Absci Q2 net loss $28.7M, exceeds Active Program guidance, restructures to extend cash to late-2025

Absci Corp

2022-Q2 EPS reported -$0.64 revenue$1,821,000

Net loss of $28.7M in Q2 2022, compared to $41.2M loss in Q2 2021.
Cash and equivalents $206.0M as of June 30, 2022, down from $252.6M at Dec 31, 2021; 2022 cash decrease expected ~$110M.
Signed ten new Active Programs year-to-date, exceeding full-year guidance of at least eight; total now 19.
Strategic reorganization reduces headcount and extends cash runway into late 2025; workforce reduction included.
Entered multi-program collaboration with undisclosed biotech for antibody-drug conjugates using Bionic technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.